Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• NaghaviM, AbajobirAA, AbbafatiC, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi:10.1016/S0140-6736(17)32-152-928919116
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic respiratory diseases: chronic obstructive pulmonary disease. Available from: https://www.who.int/respiratory/copd/burden/en/. Accessed 120, 2020.
   Google Scholar
• World Health Organization. The top 10 causes of death. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 524, 2018.
   Google Scholar
• FerkolT, SchraufnagelD. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404–406. doi:10.1513/AnnalsATS.201311-405PS24673696
   PubMedGoogle Scholar
• D’SouzaAO, ShahM, DhamaneAD, DalalAA. Clinical and economic burden of COPD in a medicaid population. COPD. 2014;11(2):212–220. doi:10.3109/15412555.2013.83616824111752
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). Available from: https://goldcopd.org/gold-reports/. Accessed 1107, 2018.
   Google Scholar
• CaiBQ, CaiSX, ChenRC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis. 2014;9:381–395. doi:10.2147/COPD.S5845424812503
   PubMed Web of Science ®Google Scholar
• RosenbergSR, KalhanR. An integrated approach to the medical treatment of chronic obstructive pulmonary disease. Med Clin N Am. 2012;96(4):811–826. doi:10.1016/j.mcn-a.2012.05.00222793946
   PubMed Web of Science ®Google Scholar
• RamseySD, HobbsFD. Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. Proc Am Thorac Soc. 2006;3(7):635–640. doi:10.1513/pats.200603-094SS16963547
   PubMedGoogle Scholar
• MullerovaH, ShuklaA, HawkinsA, QuintJ. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. doi:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJ, Martinez-GarciaMA, RomanSP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• PereraPN, ArmstrongEP, SherrillDL, SkrepnekGH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9(2):131–141. doi:10.3109/15412555.2011.65023922409371
   PubMedGoogle Scholar
• WedzichaJA, MiravitllesM, HurstJR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-201628298398
   PubMed Web of Science ®Google Scholar
• NICE Guideline Updates Team (UK). Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2018 report). Available from: https://www.nice.org.uk/. Accessed 1205, 2018.
   Google Scholar
• MaltaisF, OstinelliJ, BourbeauJ, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698–703. doi:10.1164/ajrccm.165.5.210909311874817
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTAR, PatelIS, et al. Airway and systemic inflammation and decline in lung function in patients With COPD. Chest. 2005;128(4):1995–2004. doi:10.1378/chest.128.4.199516236847
   PubMed Web of Science ®Google Scholar
• DecramerM, LacquetLM, FagardR, RogiersP. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16. doi:10.1164/ajrccm.150.1.80257358025735
   PubMed Web of Science ®Google Scholar
• McEvoyCE, EnsrudKE, BenderE, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Resp Crit Care. 1998;157(3):704–709. doi:10.1164/ajrccm.157.3.9703080
   PubMed Web of Science ®Google Scholar
• HenzenC, SuterA, LerchE, UrbinelliR, SchornoXH, BrinerVA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000;355(9203):542–545. doi:10.1016/S0140-6736(99)06290-X10683005
   PubMed Web of Science ®Google Scholar
• AkgunM. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial. Med Sci Monitor. 2014;20:513–520. doi:10.12659/MSM.890210
   PubMed Web of Science ®Google Scholar
• DingZ, LiX, LuY, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47. doi:10.1016/j.rmed.2016.1-0.01327888990
   PubMed Web of Science ®Google Scholar
• PleasantsRA, WangT, XuX, et al. Nebulized corticosteroids in the treatment of COPD exacerbations: systematic review, meta-analysis, and clinical perspective. Respir Care. 2018;63(10):1302–1310. doi:10.4187/respcare.0638430237276
   PubMed Web of Science ®Google Scholar
• ZhangJ, YaoW, YouX, LiuT, LiuY. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China. Int J Chron Obstruct Pulmon Dis. 2019;14:1195–1207. doi:10.2147/COPD.S18201531213797
   PubMed Web of Science ®Google Scholar
• EngelT, DirksenA, HeinigJH, NielsenNH, WeekeB, JohanssonSA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy. 1991;46(7):547–553. doi:10.1111/j.1398-9995.1991.tb00619.x1796780
   PubMed Web of Science ®Google Scholar
• MoriceAH, MorrisD, Lawson-MatthewP. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther. 1996;60(6):675–678. doi:10.1016/S0009-9236(96)90216-78988070
   PubMed Web of Science ®Google Scholar
• RodrigoG, RodrigoC. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998;157(3 Pt 1):698–703. doi:10.1164/ajrccm.157.3.97040229517578
   PubMed Web of Science ®Google Scholar
• RodrigoGJ. Rapid effects of inhaled corticosteroids in acute asthma. Chest. 2006;130(5):1301–1311. doi:10.1378/chest.130.5.130117099004
   PubMed Web of Science ®Google Scholar
• DerendorfH, NaveR, DrollmannA, CerasoliF, WurstW. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. doi:10.1183/09031936.0007490517074919
   PubMed Web of Science ®Google Scholar
• KumarSD, BriverJL, DantaI, WannerA. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 2000;161(3):918–921. doi:10.1164/ajrccm.161.3.990410610712343
   PubMed Web of Science ®Google Scholar
• GiembyczMA, KaurM, LeighR, NewtonR. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153(6):1090–1104. doi:10.1038/sj.bjp.0707-62718071293
   PubMed Web of Science ®Google Scholar
• ChongLK, DruryDE, DummerJF, GhahramaniP, SchleimerRP, PeachellPT. Protection by dexamethasone of the functional desensitization to beta 2-adrenoceptor-mediated responses in human lung mast cells. Br J Pharmacol. 1997;121(4):717–722. doi:10.1038/sj.bj-p.07011859208139
   PubMed Web of Science ®Google Scholar
• CaveAC, HurstMM. The use of long acting beta(2)-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis. Pharmacol Ther. 2011;130(2):114–143. doi:10.1016/j.pharmthera.2010.12.00821276815
   PubMed Web of Science ®Google Scholar
• PanettieriRA, SchaafsmaD, AmraniY, Koziol-WhiteC, OstromR, TlibaO. Non-genomic effects of glucocorticoids: an updated view. Trends Pharmacol Sci. 2019;40(1):38–49. doi:10.1016/j.tips.2018.11.00230497693
   PubMed Web of Science ®Google Scholar
• MadsenH, BrixenK, HallasJ. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. Clin Respir J. 2010;4(1):22–29. doi:10.1111/j.1752-699X.2009.00138.x20298414
   PubMed Web of Science ®Google Scholar
• GunenH, HacievliyagilSS, YetkinO, GulbasG, MutluLC, InE. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660–667. doi:10.1183/09031936.0007350617251232
   PubMed Web of Science ®Google Scholar